Evidence map›Paper›PMID 41936742›Full record

ReviewClinical rheumatology2026

Regulatory T cells as a potential treatment for autoimmune inflammatory rheumatic and musculoskeletal diseases.

Ian C Chikanza, Clementine Sifiso Nomalizo Mnkandla-Khumalo, Lazaros I Sakkas

Abstract readReview
PubMed Publisher
In one paragraph

Review in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Ian C ChikanzaFaculty of Medicine, Catholic University, Harare, Zimbabwe. i.c.chikanza@btinternet.com.ORCID http://orcid.org/0000-0001-8602-0958
Clementine Sifiso Nomalizo Mnkandla-KhumaloFaculty of Medicine, Catholic University, Harare, Zimbabwe.
Lazaros I SakkasFaculty of Medicine, School of Health Sciences, University of Thessaly, Larissa, Greece.ORCID http://orcid.org/0000-0002-7670-3314

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autoimmune diseases result from the immune system's inability to distinguish between self and non-self, destroying healthy tissue. T regulatory cells (Tregs) are a unique subset of CD4 + T cells, which play a crucial role in immune tolerance and preventing autoimmunity. Their capacity to quell an exaggerated immune reaction establishes them as a potential point for therapeutic intervention. However, utilizing Tregs' intrinsic repressive nature on other immune cells to prevent or halt autoimmunity and inflammation poses challenges in compromising pathogen clearance and in the place of restraining anti-tumor immune responses. This review outlines the biology of Tregs, their position concerning autoimmune rheumatic disease, obstacles to exploiting their therapeutic potential, and the evolution of Treg-based treatment.

Indexed as

Autoimmune DiseasesMusculoskeletal DiseasesRheumatic DiseasesT-Lymphocytes, RegulatoryAnimalsAutoimmunityHumansInflammationAnkylosing spondylitis (AS)Autoimmune diseaseAutoimmune inflammatory rheumatic and musculoskeletal disordersDiabetes mellitusGut immunityJuvenile idiopathic arthritis (JIA)Psoriatic arthritisRheumatoid arthritis (RA)SarcoidosisSystemic lupus erythematosus (SLE)Systemic sclerosisT regulatory cellsVasculitis

Identifiers

PMID41936742

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.